|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Helicobacter Infections | |||||
| Urinary Tract Infection | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Communicable Diseases | |||||
| Infection | |||||
| Urinary Tract Infections | |||||
| 3 | More general conditions related to this trial | ||||
| Bacterial Infections | |||||
| Gram-Negative Bacterial Infections | |||||
| Urologic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Finafloxacin hydrochloride | |||||
| 5 | Sponsors listed in this trial | ||||
| MerLion Pharmaceuticals GmbH | |||||